Related Experiment Video
Updated: Apr 28, 2026

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
Published on: February 14, 2018
Cryptococcal meningitis: epidemiology and therapeutic options
Derek J Sloan1, Victoria Parris1
1Tropical and infectious Disease Unit, Royal Liverpool University Hospital, Liverpool, UK.
Abstract:
Cryptococcal meningitis causes morbidity and mortality worldwide. The burden of disease is greatest in middle- and low-income countries with a high incidence of human immunodeficiency virus (HIV) infection. Patients taking immunosuppressive drugs and some immunocompetent hosts are also at risk. Treatment of cryptococcal meningitis consists of three phases: induction, consolidation, and maintenance. Effective induction therapy requires potent fungicidal drugs (amphotericin B and flucytosine), which are often unavailable in low-resource, high-endemicity settings. As a consequence, mortality is unacceptably high. Wider access to effective treatment is urgently required to improve outcomes. For human immunodeficiency virus-infected patients, judicious management of asymptomatic cryptococcal antigenemia and appropriately timed introduction of antiretroviral therapy are important.
Insights
Cryptococcal meningitis is a major global health threat, especially in low-income nations. Improving access to essential antifungal treatments is crucial to reduce high mortality rates.
Area of Science:
- Infectious Diseases
- Mycology
- Public Health
Background:
- Cryptococcal meningitis is a significant cause of illness and death globally.
- High-risk populations include those with human immunodeficiency virus (HIV) infection and individuals on immunosuppressive therapy.
- The disease disproportionately affects middle- and low-income countries.
Purpose of the Study:
- To highlight the global burden of cryptococcal meningitis.
- To emphasize the challenges in accessing effective treatment, particularly in resource-limited settings.
- To underscore the need for improved therapeutic strategies and management protocols.
Main Methods:
- Review of existing literature on cryptococcal meningitis epidemiology and treatment.
- Analysis of treatment phases: induction, consolidation, and maintenance.
- Discussion of drug availability and accessibility issues.
Main Results:
- Effective induction therapy relies on amphotericin B and flucytosine, often unavailable in high-burden regions.
- Lack of access to potent fungicidal drugs contributes to unacceptably high mortality rates.
- Management of cryptococcal antigenemia and timely antiretroviral therapy are critical for HIV-infected patients.
Conclusions:
- Wider access to effective antifungal treatments is urgently needed to improve patient outcomes.
- Addressing treatment accessibility in low-resource settings is paramount.
- Integrated management strategies, including antiretroviral therapy, are essential for combating cryptococcal meningitis.
Related Concept Videos
Fungal Phylum Microsporidia
Antifungal Agents
Bacterial Meningitis II: Pathophysiology
Bacterial Meningitis I: Introduction
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Viral Meningitis

